Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

University of Lille

www.univ-lille3.fr

Latest From University of Lille

AlzProtect SAS

AlzProtect SAS believes that Alzheimer's disease is caused by the loss of neuroprotective factors including APP intracellular domain and sAPP alpha, both of which are produced during the metabolism of amyloid precursor protein. The start-up is developing compounds that can stimulate the APP, increasing the production of neuroprotective compounds.
BioPharmaceutical

Can France Stay in the Game?

The French government's efforts to encourage biotechnology have been modest and somewhat piecemeal. Yet two years ago, France's industry was nevertheless ranked second in Europe. Since then, the explosion of biotech companies in Germany, along with steady growth in other European markets, make the need for a coherent French strategy more urgent. France needs to take some bolder, more generous measures--particularly to reduce companies' tax burden and attract talent from overseas--without which it risks restricting itself to a small group of companies, many of whom will have to move elsewhere to grow substantially.
BioPharmaceutical Europe
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register